CEPI, alongside Gavi and the World Health Organisation, launched COVAX – the vaccines pillar of the ACT Accelerator – with the aim of ending the acute phase of the pandemic by the end of 2021.

COVAX is the only solution that will deliver fair, equitable access to vaccines for every country that participates.

It aims to provide an ‘end-to-end’ solution to the challenge of vaccine development, manufacture and supply in this pandemic – bringing together the skills, expertise and resources of the public, private and philanthropic sectors on a global scale.

Together we aim to produce 2 billion doses of vaccine and distribute them globally and fairly in 2021. To support the vaccine R&D that is critical to achieving this goal, CEPI estimates that it needs $2.1bn to progress three vaccines to licensure, which will be made available to the world through COVAX.

Through COVAX, the risks and benefits of developing and producing vaccines are shared across countries. COVAX works by pooling financial resources to develop vaccines, purchase them at scale, and investing up-front in manufacturing so that vaccines are ready to be distributed as soon as they are licensed.

Countries participating in COVAX can access CEPI’s portfolio of COVID-19 vaccine candidates – the largest in the world – which is managed by CEPI’s R&D experts. CEPI’s approach of backing a diverse range of vaccine candidates increases our chances of developing multiple successful vaccines, which is crucial if we are to meet demand and protect the most vulnerable.

Find out more about COVAX and the CEPI COVID-19 vaccine portfolio here.


COVAX work streams

Four SWAT teams within COVAX have been created to focus on critical areas related to vaccine development, with overarching guidance from the COVAX Regulatory Advisory Group.

Enabling Sciences
The Enabling Sciences SWAT team provides cross-cutting support to COVID-19 vaccine developers in the area of diagnostics, standards, assays and animal models.

Clinical Development and Operations  
The Clinical Development and Operations SWAT team collaborates on initiatives related to clinical operations (incl.  supporting trial site readiness and setting up a clinical trial site network, providing information on COVID-19 CTA and EC requirements for specific regions), vaccine safety (incl. AESIs / case definitions, post roll-out vaccine safety surveillance), vaccine science (incl. development of strategic documents on key topics such as standard CT elements, adaptive trial design, Correlate of Protection, alternative/supportive evidence, optimization options) and maternal immunization. 

The Manufacturing SWAT team provides cross-cutting support to COVID-19 vaccine developers in the area of Drug Substance (DS) and Drug Product (DP) scale-up and scale-out, supply chain and release assays.

Regulatory Advisory Group
The COVAX Regulatory Advisory Group works to address regulatory issues and challenges identified by the enabling sciences, clinical development and operations, and manufacturing SWAT teams.